All Type of News
Medium-sized DongKwang Pharm successfully avoids KRW 10 billion ‘Cancidas’ patent
A medium pharmaceutical company DongKwang Pharmaceutical raised a chance for the early launch of Cancidas(caspofungin acetate, MSD Korea), antifungal, through avoiding its patent alone.
Since it is the patent other c...
Domestic pharmaceuticals record 57% cost/sales rate, causing on marketability
It was observed the domestic pharmaceutical companies’ cost/sales rate was 57% on average, and was approximately 10% lower than the one of multinational pharmaceutical companies branched in Korea.
It basically shows ...
Tai Guk Pharm acquires dermatological EU-GMP for first time in KoreaTai Guk Pharm(CEO Chang-gu Lee), the largest domestic pharmaceutical company specializing in dermatological products, announced acquisition of the pharmaceutical EU-GMP(Europe G...
|
A series of defeats by domestic pharmaceuticals in patent challenges
Domestic pharmaceutical companies were defeated from patent suits in series. They were against substance patents of Ezetrol(ezetimibe), Forxiga(dapagliflozin) and Pradaxa(dabigatran etexilate) and a crystalline patent...
Long-cherished wish will be addressed for distribution companies
The government has prepared a special measure for shortage-prevented pharmaceutical products that are necessary to treat patients not to encounter difficulties in supply.
It basically decided to prohibit selling prod...
Multinational pharmaceuticals keep 3 months to collect drug payments
Multinational pharmaceutical companies branched in the Korean market were observed to take about 3 months on average to collect payments from selling pharmaceutical products.
The length was a month faster than domest...
Domestic pharmaceuticals made KRW 94 from selling product of KRW 1,000 last year
Domestic pharmaceutical companies were observed to earn KRW 94 from selling a product worth of KRW 1,000 last year.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of 2015 audit reports turned in by ...
Debate over possibility of smoking cessation on own will
The 8th defense for the damage suit filed by the National Health Insurance Corporation(NHIS) against KT&G, Philip Morris Korea and BAT Korea opened at the courtroom 466 of the Seoul Central District Court at 2pm on th...
New Baxalta drug emerges in Pfizer-monopolizing hemophilia B market
In the domestic hemophilia B(congenital factor ix deficiency) market which had been monopolized by Pfizer with Benefix, a rival emerged.
Recently, the Ministry of Health and Welfare(MOHW) administratively notified t...
Will the humidifier germicide death case fuel boycotts against Gaviscon and Strepsils?
Criticism on RB Korea(Oxy Reckitt Benckiser) which was indicated to generate the highest number of victims at the humidifier germicide death case has widely spread.
In the circumstance, the pharmacy world which dea...
